Seelos Therapeutics, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 1 | -$152.49 | -$152.49 | -$152.49 |
| Q2 2024 | 1 | -$162.09 | -$162.09 | -$162.09 |
| Q3 2024 | 1 | -$83.70 | -$83.70 | -$83.70 |
Seelos Therapeutics, Inc. Earnings Date And Information
Seelos Therapeutics, Inc. last posted its earnings results on Tuesday, May 14th, 2024. The company reported $-25.6 earnings per share for the quarter, missing analysts' consensus estimates of $-1.48 by $24.12. The company had revenue of 376,000 for the quarter and had revenue of 2.20 M for the year. Seelos Therapeutics, Inc. has generated $-8 earnings per share over the last year ($-7.73 diluted earnings per share) and currently has a price-to-earnings ratio of 0.11. Seelos Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 14th, 2024 based on prior year's report dates.
Seelos Therapeutics, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 08/14/2024 | Q2 2024 | $0.36 | $376,000 | $376,000 | ||
| 03/29/2024 | Q1 2024 | -$0.20 | $579,000 | |||
| 12/29/2023 | Q4 2023 | -$0.56 | $653,000 | |||
| 11/14/2023 | Q3 2023 | -$0.06 | $2.33 | 2.39 | $150,000 | $406,000 |
| 08/11/2023 | Q2 2023 | -$6.71 | $336,000 | |||
| 05/12/2023 | Q1 2023 | -$4.60 | $808,000 | |||
| 03/09/2023 | Q4 2022 | -$0.13 | -$5.33 | -5.2 | $0 | |
| 11/10/2022 | Q3 2022 | -$0.10 | -$6.13 | -6.03 | $0 | |
| 08/05/2022 | Q2 2022 | -$1,153.15 | -$6.02 | 1147.13 | $0 | |
| 05/10/2022 | Q1 2022 | -$1,076.28 | -$3.98 | 1072.3 | $0 | |
| 03/04/2022 | Q4 2021 | -$7.75 | $0 | |||
| 11/05/2021 | Q3 2021 | -$345.95 | -$3.17 | 342.78 | $0 | |
| 08/06/2021 | Q2 2021 | -$3.02 | $0 | |||
| 04/30/2021 | Q1 2021 | -$0.09 | -$8.30 | -8.21 | $0 | |
| 03/11/2021 | Q4 2020 | -$0.08 | -$3.60 | -3.52 | $14.30 M | |
| 11/12/2020 | Q3 2020 | -$0.08 | -$2.61 | -2.53 | $0 | |
| 08/13/2020 | Q2 2020 | -$422.82 | -$2.53 | 420.29 | $0 | |
| 05/07/2020 | Q1 2020 | -$615.02 | -$4.25 | 610.77 | $0 | |
| 03/17/2020 | Q4 2019 | -$0.16 | -$11.41 | -11.25 | $375,000 | |
| 11/07/2019 | Q3 2019 | -$461.26 | -$4.00 | 457.26 | $375,000 |
Seelos Therapeutics, Inc. Earnings: Frequently Asked Questions
-
When is Seelos Therapeutics, Inc.'s earnings date?
Seelos Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 14th, 2024 based off last year's report dates.
-
How can I listen to Seelos Therapeutics, Inc.'s earnings conference call?
The conference call for Seelos Therapeutics, Inc.'s latest earnings report can be listened to online.
-
How can I read Seelos Therapeutics, Inc.'s conference call transcript?
The conference call transcript for Seelos Therapeutics, Inc.'s latest earnings report can be read online.
-
How much revenue does Seelos Therapeutics, Inc. generate each year?
Seelos Therapeutics, Inc. (:SEEL) has a recorded annual revenue of $2.20 M.
-
How much profit does Seelos Therapeutics, Inc. generate each year?
Seelos Therapeutics, Inc. (:SEEL) has a recorded net income of $2.20 M. Seelos Therapeutics, Inc. has generated $-7.73 earnings per share over the last four quarters.
-
What is Seelos Therapeutics, Inc.'s price-to-earnings ratio?
Seelos Therapeutics, Inc. (:SEEL) has a price-to-earnings ratio of 0.11 and price/earnings-to-growth ratio is 0.
